Ignyta Announces Underwriters’ Full Exercise of Option to Purchase Additional Shares in Public Offering of Common Stock
SAN DIEGO--Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, today announced the underwriters’ full exercise of the option granted to the underwriters to purchase an additional 786,750 shares of the company’s common stock, at a price to the public of $9.15 per share. The option to purchase the additional shares was granted in connection with the company's previously announced underwritten public offering of 5,245,000 shares of its common stock. The exercise of the option brings the expected total gross proceeds from the offering to approximately $55.2 million.
Net proceeds, after deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $51.3 million. The offering is expected to close on March 19, 2014, subject to customary closing conditions.
Leerink Partners LLC is acting as book-running manager for the offering. Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc. (NYSE MKT: LTS), is acting as co-lead manager for the offering.
A registration statement on Form S-1 relating to the shares of common stock being sold was declared effective by the Securities and Exchange Commission on March 13, 2014. A final prospectus relating to the offering has been filed with the SEC. Copies of the final prospectus may be obtained from Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or by email at syndicate@Leerink.com, or by phone at (800) 808-7525.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Ignyta, Inc.
Ignyta, Inc., located in San Diego, California, is a biotechnology company developing precision medicine with integrated Rx/Dx solutions for cancer patients. Its goal is to discover and develop revolutionary new drugs that target activated genes in cancer cells for the customized treatment of cancer patients. The company’s present focus is on the development of RXDX-101, its proprietary oral tyrosine kinase inhibitor that targets solid tumor indications, and advancing its novel Spark discovery programs that leverage its proprietary cancer genomic and epigenomic knowledge bases.
This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Forward-looking statements in this release include, among other things, statements regarding the completion of the offering and the expected net proceeds therefrom. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, market risks and uncertainties, the satisfaction of customary closing conditions for the offering and other risks described in Ignyta’s filings with the Securities and Exchange Commission. These forward-looking statements are made as of the date of this press release, and Ignyta assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.